Toggle navigation
About Us
Science & Innovation
Products and Resources
Our Responsibility
Careers
Investors
Media
Toggle navigation
Press Releases
Featured News
Press Statements
Subscribe
Media Contacts
Social Media
Press Releases
Year
All Years
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Oct 20, 2020
Sanofi and Merck to present three new studies highlighting combination pediatric vaccines at IDWeek 2020
Oct 13, 2020
Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option
Sep 21, 2020
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy
Sep 18, 2020
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial
Sep 14, 2020
FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
* Designation based on positive results from Part A of pivotal Phase 3 trial
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
169
»
Print
Email page
RSS